BioHealth Capital Region – Regional Life Sciences Roundup – November 11, 2026
The week in the BioHealth Capital Region ran capital and commercial momentum through every stage of development.
Luminoah, a medical technology company based in Virginia, closed a $25 million Series B led by Sandbox Clinical Ventures to expand distribution of Luminoah Flow, its FDA-cleared enteral feeding system. Meanwhile, TriGemX Bio appointed biotechnology industry veteran Daniel Lynch as chairman of its board as the company advances its Phase 3 migraine treatment candidate and prepares for a proposed merger with TCGX Acquisition Corp., a publicly traded special purpose acquisition company.
The people and workforce side moved early too. Regenerative medicine company Theradaptive celebrated the opening of its $15 million manufacturing expansion in Frederick with a ribbon-cutting ceremony on October 29. The 23,000-square-foot facility brings commercial-scale GMP manufacturing in-house, placing the company’s research, development, and production under one roof. Theradaptive now employs 53 people and says the site could grow to as many as 100 employees within five years. Across the region, industry leaders gathered at Loyola University Maryland to speak directly with students about career paths beyond the lab bench, reinforcing that life sciences companies need lawyers, business developers, and operators as much as they need bench scientists.
Financial
Tracking the capital moving through the BioHealth Capital Region: funding rounds, M&A activity, and investment trends shaping Maryland, DC, and Virginia’s life sciences companies.
Maryland announces stem cell funding with upcoming deadline
The Maryland Stem Cell Research Commission announced new funding opportunities through the Maryland Stem Cell Research Fund. Applications are invited for projects advancing stem cell research and regenerative medicine. Details on eligible projects, funding amounts, and application deadlines are available through the commission. Read More >
Virginia medtech lands $25 million for FDA-cleared feeding system rollout
Luminoah, a medical technology company based in Virginia, raised $25 million in Series B financing led by Sandbox Clinical Ventures. The round included participation from Blue Venture Fund, GV, Sands Capital, Texas Medical Center Venture Fund, CU Healthcare Innovation Fund, and the AGA GI Opportunity Fund. The funding will support expanded distribution of Luminoah Flow, the company’s FDA-cleared enteral feeding system, and continued development of its clinician-facing data platform. Read More >
$168 million federal award targets rural health workforce and infrastructure
Governor Moore announced that the Maryland Department of Health received $168 million in year two federal funding to strengthen rural health infrastructure and services. The award supports expanded access to care, workforce development, and health system capacity in rural communities across Maryland. Read More >
Women Building Bio 2026: Rising Founders and a VC’s Advice
Virginia Bio held its Women Building Bio event on October 29 in Alexandria, pairing a keynote from Deborah Hemingway of Ecphora Capital with a startup pitch showcase. Hemingway advised founders that investors look for de-risked opportunities backed by customer discovery, technical feasibility, and strong teams, pointing to NSF I-Corps as a resource. Three women founders pitched companies built from personal experience: Healp, an AI platform matching undiagnosed patients with similar cases (100,000 users in 70 countries), and iRays, developing a handheld pupillometer for first responders now in Read More >
People
Who we’re buzzing about this week: the leadership moves, board appointments, and rising names shaping the region’s life sciences community.
This Frederick lab facility is changing who can move in, here’s the new tenant mix
Doug Bane, founder and CEO of Bane Bio and I270 Tech Labs, spoke with BioBuzz about the Frederick facility’s rebrand from I270 Innovation Labs to I270 Tech Labs. The rebrand opens the doors more broadly to technology companies while continuing to serve the biotech community. The facility provides lab space, equipment, and infrastructure designed to lower startup costs for early-stage companies. Read More >
TriGemX Bio names new chairman as TCGX Acquisition Corp. deal approaches
TriGemX Bio appointed Daniel Lynch as chairman of its board of directors as the company advances its Phase 3 migraine treatment candidate and prepares for a proposed merger with TCGX Acquisition Corp. Lynch brings more than 30 years of leadership experience across biotechnology and pharmaceutical companies and will continue as chairman following the transaction’s close. Read More >
Workforce
The hiring activity, team expansions, and talent trends driving growth across Maryland, DC, and Virginia’s life sciences and biotech employers.
Industry panel at Loyola covered six life sciences careers that don’t require lab work
Six industry professionals from across the BioHealth Capital Region spoke with students at Loyola University Maryland on October 22 about career paths in life sciences that extend beyond the lab bench. The panel included leaders from AstraZeneca, BioBuild, Covered Commerce, Beaufort CRO, Buck Branch Advisory, and BioBuzz, representing drug development, clinical research, entrepreneurship, business, law, and operations roles. Read More >
What did Theradaptive’s $15M Frederick facility just make possible that wasn’t before?
Theradaptive, a regenerative medicine company in Frederick, celebrated the opening of its $15 million, 23,000-square-foot GMP manufacturing expansion on October 29 with a ribbon-cutting ceremony attended by elected officials and government representatives. The facility brings commercial-scale manufacturing in-house and positions the company to grow from 53 employees to as many as 100 within five years. Read More >
Hood College partners with county workforce services for data analytics program
Hood College’s Bioscience Research and Education Center and Frederick County Workforce Services entered into a partnership to provide Maryland residents with training in data analytics and artificial intelligence. The partnership will fund two cohorts of an AI-Enhanced Data Analytics Program to be delivered during spring 2027 and fall 2027, designed to serve unemployed, underemployed, and workers seeking skills in growing sectors. Read More >
Who’s Hiring
| TOP EMPLOYER | ||||||
| ||||||
| View all jobs on BioBuzz |
Clinical + Commercial
The latest clinical trial progress, regulatory milestones, and commercial launches from companies advancing science from the lab to the market across the BioHealth Capital Region.
33% of lung cancer patients in OncoC4 trial showed tumor response after earlier treatment resistance
Rockville-based OncoC4 reported encouraging Phase 1/2 results for cesalatamig (AI-081), its investigational PD-1/VEGF bispecific antibody, in patients with PD-(L)1-resistant or refractory non-small cell lung cancer. The pooled analysis presented at the Society for Immunotherapy of Cancer Annual Meeting showed a 33% investigator-assessed objective response rate and 90% disease control rate at 10 mg/kg every three weeks. The safety profile was manageable across all dose levels. Read More >
AbelZeta shares Phase 1 data on GPC3-targeted CAR-T in 36 liver cancer patients
Rockville-based AbelZeta presented updated Phase 1 clinical results for C-CAR031 (now known as AZD7003), a GPC3-targeted armored CAR-T therapy in advanced hepatocellular carcinoma, at the European Society for Medical Oncology Congress 2026 in Madrid. The study of 36 heavily pretreated patients demonstrated a 7% disease control rate across all dose levels, with deep tumor shrinkages and an encouraging survival signal. Median follow-up was 9 months as of the August 15 data cutoff. Read More >
GeneDx study of 300,000 patients reveals how often genetic findings lead to clinical action
GeneDx, based in Gaithersburg, presented research at the National Society of Genetic Counselors Annual Conference showing that 62% of patients with pathogenic or likely pathogenic findings from exome and genome sequencing had results associated with medical actionability. The real-world study analyzed data from more than 300,000 patients and identified opportunities to inform treatment, disease surveillance, acute management, and long-term care. Read More >
Ecosystem
The partnerships, programs, and policy moves building the BioHealth Capital Region’s life sciences infrastructure, and the organizations driving it forward.
NIH licenses imaging agent to Maryland startup preparing FDA submission
The National Institutes of Health licensed BL-760, a near-infrared fluorescence imaging agent for surgical visualization, to Maryland-based Optosurgical for clinical development. The investigational agent is designed to help surgeons see bile ducts and related anatomy in real time during laparoscopic gallbladder removal, potentially reducing surgical injury risk. Optosurgical is preparing an FDA submission and planning a Phase 1b study to examine BL-760’s safety, tolerability and imaging performance, with support from ARPA-H funding. Read More >
TEDCO opens RFP for legal and regulatory consultants to support biotech portfolio
TEDCO issued a request for proposals from legal, regulatory, and scientific research consulting services. The request seeks qualified firms to provide specialized support for TEDCO’s portfolio companies and program operations. Details on proposal requirements and submission deadlines are available through TEDCO. Read More >
Incyte awards GVHD research grants to Maryland and Moffitt teams for AI screening and patient support
University of Maryland School of Medicine will develop an AI-enabled screening platform to support earlier identification and referral of patients with ocular GVHD. H. Lee Moffitt Cancer Center & Research Institute plans to advance understanding of the unique challenges and support needs of Read More >
Other [Good] Reads
Editor’s picks from across the web: the stories, videos, and podcasts shaping the conversation in DMV biotech and life sciences this week.
Small molecule drug product capacity and capabilities
Bora Pharmaceuticals hosted an on-demand webinar exploring the company’s small molecule drug product manufacturing capabilities, available capacity, technology transfer processes, and recent investments across its global CDMO network. The session highlighted oral solid dose, liquid, semi-solid, and ophthalmic manufacturing capabilities, including specialized expertise in high-potency APIs and controlled substances. Read More >
AbbVie’s Sean Kelley on what separates a discovery from a treatment
Sean Kelley, Vice President for neuroscience and toxins, Portfolio Strategy and Program Leadership at AbbVie, discussed the development factors that determine whether a promising discovery becomes a medicine that reaches patients on the Business of Biotech podcast. The episode covered risk management and portfolio development in a growing neuroscience pipeline. Read More >
How did a rescue study go from zero to first patient in two months?
Precision for Medicine published a case study on how operational readiness and adaptable project management built a repeatable early-phase oncology study model. A rescue study reached first patient in within two months, then established repeatable startup, communication, and project-management practices for a growing early-phase oncology program. Read More >
On the Calendar
A few of the upcoming events, conferences, and networking opportunities across the BioHealth Capital Region’s life sciences ecosystem that you don’t want to miss.
Policy & Strategy: Shaping the Future of Life Sciences
Tuesday, November 17 · 4:30 PM–7:00 PM · Womble Bond Dickinson, McLean, VA
Hosted by Virginia Bio | Register Now >
Technology Symposium Series: AI and Biotech
Wednesday, November 18 · 8:30 AM–1:30 PM · Laurel, Maryland
Hosted by Maryland Tech Council | Register Now >
GxP Auditing Logistics and Inspection Readiness Training Course (Including Mock Activity)
Thursday-Friday, November 19-20 · Bethesda, MD
Hosted by PDA | Register Now >
Did we miss something!? Drop us a line →
Stay connected to BioHealth Capital Region life sciences.
